Levetiracetam Ratiopharm

Levetiracetam, the active ingredient in Levetiracetam Ratiopharm, is an anticonvulsant presented as a tablet for oral use. It is prescribed to control various seizure types in patients with epilepsy.

GNH USA supplies Levetiracetam Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic medication that reduces neuronal hyperexcitability across several seizure disorders.

Partial seizures: helps achieve seizure control by decreasing the frequency of focal events. Generalized tonic‑clonic seizures: reduces the occurrence of convulsive episodes. Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with this seizure type.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (e.g., anaphylaxis) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or behavior - Blood dyscrasias (e.g., neutropenia, thrombocytopenia) - Severe skin rash - Multi‑organ hypersensitivity syndrome

Before initiating therapy, several safety considerations should be reviewed.

Monitor renal function: dose adjustments may be required in renal impairment. Avoid abrupt discontinuation: tapering reduces risk of seizure recurrence. Assess psychiatric history: levetiracetam can exacerbate mood changes. Pregnancy and lactation: safety data are limited; use only if clearly needed. Drug‑specific counseling: advise patients to report new mood or behavioral changes promptly. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Phenytoin: can reduce levetiracetam levels, decreasing seizure control. - Phenobarbital: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Central nervous system depressants: may increase sedation. - Alcohol: can enhance dizziness and drowsiness.